Mastocytosis - Pipeline Insight, 2024

Mastocytosis - Pipeline Insight, 2024

DelveInsight’s, Mastocytosis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mastocytosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mastocytosis Understanding

Mastocytosis: Overview

Systemic mastocytosis is an aggressive disorder characterized by the release of numerous vasoactive cell mediators due to excessive activity of mast cells, which results in a wide variety of symptoms. Symptoms include anaphylaxis, flushing, nonspecific GI as well as neuropsychiatric complaints.

Mast cells are immune cells derived from myeloid lineage. They are usually located in the connective tissues. They are activated through immunoglobulin (Ig)E mediated and non-IgE mechanisms and thus act as effector cells in hypersensitivity and allergic reactions. In the IgE mediated mechanism, the allergen forms a cross-link with the IgE receptor, which then activates the mast cells, resulting in degranulation. Non-IgE mediated mechanisms include emotional and physical stimuli, food, drugs like opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, heat, exercise, cytokines, venoms, and hormones. The most common mediators released are histamines, proteases, cytokines, growth hormones, tumor necrosis factors, and phospholipases. Tryptases and chymases form an abundant portion of the mast cell granules. Tryptase is almost always secreted by mast cells and therefore it is used as an important diagnostic factor

""Mastocytosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mastocytosis pipeline landscape is provided which includes the disease overview and Mastocytosis treatment guidelines. The assessment part of the report embraces, in depth Mastocytosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mastocytosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Mastocytosis. The therapies under development are focused on novel approaches to treat/improve Mastocytosis.

Mastocytosis Emerging Drugs

Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology, masitinib has the potential to improve survival when administered alone or in combination with chemotherapy via targeting of specific gene mutations or because of its immunotherapeutic properties. Masitinib can exert a neuroprotective effect in some central nervous system diseases and reduce symptoms in some chronic inflammatory disorders through its activity on mast cells and microglia, with subsequent modulation of inflammatory and neurodegenerative processes.

Ripretinib: Deciphera Pharmaceuticals

Ripretinib is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop1 and 2.

Further product details are provided in the report……..

Mastocytosis: Therapeutic Assessment

This segment of the report provides insights about the Mastocytosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Mastocytosis

There are approx. 10+ key companies which are developing the therapies Mastocytosis. The companies which have their Mastocytosis drug candidates in the most advanced stage, i.e phase III include AB Science

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mastocytosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mastocytosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mastocytosis drugs.

Mastocytosis Report Insights

• Mastocytosis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mastocytosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mastocytosis drugs?
• How many Mastocytosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mastocytosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mastocytosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mastocytosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cogent Biosciences
• Deciphera Pharmaceuticals
• AB Science
• Pfizer
• Novelty Nobility
• Blueprint Medicines

Key Products

• Bezuclastinib
• Ripretinib
• Masitinib
• Crenolanib
• NN 3901
• BLU 263